Our Medical Establishment In Power Versus Our Medical Establishment Out of Power

“The medical establishment” is one of those phrases that can mean “my doctor and the hospital down the street”
or “a shadowy cabal that meets under a full moon and decides which vitamins are allowed to be fun.”
In real life, it’s neither a single villain nor a single hero. It’s a crowded ecosystem: federal and state agencies,
insurers, hospitals, academic medicine, professional societies, public health departments, and industryeach with
different incentives, budgets, legal powers, and blind spots.

So what does it mean when the medical establishment is “in power” versus “out of power”? Think of “power” in two
ways: formal power (who can write rules, pay bills, approve products, and enforce standards) and
informal power (who shapes the norms, the evidence, the headlines, and the professional consensus).
Sometimes those two line up. Sometimes they fight like siblings in the back seat on a road trip.

What People Mean by “Medical Establishment”

In the U.S., healthcare isn’t one systemit’s a stack of systems. When people say “medical establishment,” they’re
usually pointing at some combination of:

• Regulators (e.g., agencies that oversee drugs, devices, and public health).
• Payers (e.g., Medicare/Medicaid and private insurance deciding what gets reimbursed and how).
• Providers (hospitals, clinics, physician groups, nursing homes).
• Knowledge-makers (research universities, guideline panels, journals, public health experts).
• Industry (pharma, biotech, medical devices, labs, PBMs, health tech, private equity-backed services).
• Professional organizations (groups that advocate for clinicians or set standards of practice).

This matters because the “establishment” doesn’t always move as one unit. A public health agency might want broad
prevention; a payer might want cost control; a hospital might want stable reimbursement; a patient group might want
access; a drugmaker might want a faster pathway and broader coverage. Same ecosystem, different “power buttons.”

When the Medical Establishment Is “In Power”

“In power” usually means the establishment’s priorities are aligned with the levers of government and financing.
It doesn’t require a conspiracy; it only requires control of the ordinary machinery that makes U.S. healthcare
runapprovals, payment policy, budgets, and guidance.

1) The power to approve (and define) what counts as medicine

In a practical sense, approval and regulation are gatekeeping functions. If a product can’t be legally marketed,
prescribed, reimbursed, or trusted, it struggles to exist at scale. U.S. regulators determine how drugs and devices
are reviewed, what evidence is required, how safety is monitored, and what labels can say. That’s “in power” in the
most literal sense: the ability to say “yes,” “no,” or “not yet.”

2) The power to pay (and thereby shape behavior)

Payment policy is the quiet giant of healthcare power. When reimbursement changes, behavior changessometimes
slowly, sometimes overnight. If reimbursement rewards volume, you get volume. If it rewards outcomes, you get more
reporting (and, occasionally, outcomes). If it penalizes readmissions, hospitals invest in discharge planning.

Medicare and Medicaid don’t just pay bills; they influence standards because their scale is enormous. Private
insurers often mirror Medicare policies or use them as reference points. When the establishment is “in power,” it
can translate priorities (quality measures, preventive care, value-based payment models) into dollars and billing
codesthe closest thing America has to a national “steering wheel.”

3) The power to set national priorities through research funding

Research budgets are not just science; they’re strategy. When federal research funding prioritizes one area,
universities hire for it, trainees pursue it, and industry forms around it. That’s not inherently badit’s often how
the U.S. accelerates breakthroughs. But it is power: deciding which questions get asked, which technologies mature,
and which conditions get the most attention.

4) The power of “official guidance” in crises

During a public health emergency, the “establishment in power” becomes highly visible: guidance, dashboards,
recommendations, and high-stakes messaging. Even when guidance isn’t legally binding, it becomes the reference
point for schools, employers, clinicians, and news outlets. And once guidance is “official,” it can shape liability,
payer rules, and professional standardswithout passing a single new law.

5) The power to standardize care through guidelines and quality measures

Guidelines are a special kind of influence. They are often not laws, but they can become the backbone of
“best practice,” malpractice arguments, insurance coverage decisions, and performance measurement. The establishment
is “in power” when its guideline ecosystem (panels, societies, evidence reviews, and payer adoption) moves in the
same direction.

When the Medical Establishment Is “Out of Power”

“Out of power” doesn’t mean powerless. It usually means the formal levers (government leadership, budgets, rulemaking
priorities) are controlled by people or coalitions who disagree with the establishment’s dominant preferencesor who
want to reorganize who counts as “the establishment.”

1) Influence shifts from rulemaking to persuasion

If you can’t write the rules, you try to shape the room. That can look like publishing evidence, public letters,
consensus statements, op-eds, testimony, and “this will backfire” memos. In medicine, persuasion can be powerful
because credibility is a form of currency. The establishment out of formal power leans harder on its informal power:
science, professional norms, and trusted messengers.

2) Litigation and the courts become a battleground

Health policy regularly ends up in court. When the establishment is out of power, legal challenges can become the
“back door” to shape national policyeither to block policies it opposes or to defend policies it supports. Court
decisions can preserve, narrow, or reinterpret the authority of agencies and expert bodies, changing how much
“expert recommendation” can translate into real-world coverage and access.

3) The “revolving door” and lobbying fill the gap

Healthcare is one of the biggest lobbying arenas in the U.S., and it’s not just drugmakers. Hospitals, insurers,
professional groups, and health services companies all fight for favorable rules and reimbursement. When the
establishment is out of power, it often invests more in lobbying, coalition-building, and incremental winsbecause
sweeping reforms are harder when you don’t control the pen.

4) State-level policy becomes more important

If federal leadership is unfriendly, the action shifts to states: licensing rules, scope-of-practice battles,
Medicaid decisions, public health regulations, and insurance mandates. An establishment “out of power” federally may
try to build momentum through state experiments and then scale what works.

Four Case Studies That Show “Power” in Action

Case Study 1: Preventive carewhen recommendations become coverage

Preventive care is a clean example of how informal expert judgment becomes formal access. Under the Affordable Care
Act, many preventive services have been covered without cost-sharing, which can boost uptake for screenings and
prevention. But that pipeline depends on the legal and administrative structure behind expert recommendations.

When courts weigh in, “out of power” strategies can become decisive. A major Supreme Court decision in 2025 upheld a
key element of no-cost preventive care tied to expert recommendations, showing how the judiciary can preserve (or
potentially unwind) the practical effects of expert panels without changing the science itself.

Case Study 2: Drug pricingMedicare negotiation and the politics of affordability

Drug pricing is where the establishment’s factions visibly collide: patients want affordability, manufacturers want
returns and predictable rules, payers want leverage, and policymakers want both savings and innovation. Medicare’s
drug price negotiation program illustrates “establishment in power” because it turns policy into direct purchasing
leveragereal dollars, real timelines, real consequences.

Even when the establishment is “out of power,” these programs can be hard to remove once implemented, because they
create constituencies: beneficiaries who benefit, budgets that depend on savings, and market expectations. That’s why
many fights shift from “kill it” to “edit it”: exemptions, timelines, implementation details, and which drugs are
targeted.

Case Study 3: Opioid prescribingguidelines that are not laws (but still matter)

The opioid crisis put guideline power under a spotlight. Federal public health guidance on prescribing is explicitly
not the same as a law, yet it can influence payer policies, clinician behavior, state rules, and professional norms.
When the establishment is “in power,” guidance can become a national reference point. When it’s “out of power,” the
debates intensify: critics argue about unintended consequences, supporters argue about harm reduction and safer care.

Either way, this is what “soft power” looks like in medicine: a document can change practice patterns because it
changes what is considered defensible, reimbursable, and professionally standardeven without legal force.

Case Study 4: Consolidationmarket power versus medical authority

Here’s the twist: sometimes “the medical establishment” isn’t the most powerful actor in the room. In many markets,
consolidated health systems, vertically integrated insurers, and private equity-backed services can wield enormous
negotiating leverage. Antitrust enforcement and competition policy can become a counterweightan area where
government action can curb market power that drives prices and limits choices.

Why This Tension Isn’t Always Bad

It’s tempting to root for one side: “Experts should run everything” or “Experts should run nothing.” But healthcare
is too complicated for either extreme. A healthy system has productive friction:

• Expertise to evaluate evidence and avoid magical thinking.
• Democratic accountability to ensure policies reflect public values and tradeoffs.
• Transparency so people can see incentives, conflicts, and assumptions.
• Competition and oversight so no single institution can overcharge, under-deliver, or self-deal.

When the establishment is “in power,” the risk is overconfidence: treating a guideline like a commandment, or
mistaking “average evidence” for “every patient.” When it’s “out of power,” the risk is whiplash: constant policy
shifts, underfunded public health, and healthcare decisions driven more by ideology than outcomes.

How “In Power” vs “Out of Power” Changes What You Feel as a Patient

Most people don’t experience healthcare as “policy.” They experience it as: “Is this covered?” “How long is the
wait?” “Why does the pharmacy want a second mortgage?” That’s where the power shift becomes personal.

Coverage and cost

When establishment-aligned policies prioritize prevention and access, you may see more no-cost screenings,
standardized benefits, or expanded coverage pathways. When leadership prioritizes cost containment or deregulation,
you may see more experimentation with payment models, shifting benefit designs, or tighter eligibility rules.

Access and availability

Payment rules influence which clinics stay open, which specialties expand, and how aggressively health systems hire.
Research priorities influence which treatments become available in five years. Competition policy influences whether
you have one hospital system (that sets prices like it’s selling concert tickets) or several that have to compete for
your business.

Trust and communication

Trust rises when guidance is clear, consistent, and humble about uncertainty. Trust falls when institutions appear
defensive, political, or captured by special interests. “In power” can feel stabilizingor paternalistic. “Out of
power” can feel liberatingor chaotic. Context matters.

Practical Ways to Navigate the System Without Losing Your Mind

• Separate “evidence” from “policy.” Evidence answers “what tends to work.” Policy answers “what will we pay for, and for whom?”
• Ask the money question (politely). “Is this covered?” “What’s the cash price?” “Is there a lower-cost equivalent?”
• Use preventive benefits. If your plan covers preventive services with no cost sharing, treat that like a buy-one-get-one coupon from the universe.
• Watch for consolidation. Fewer choices often means higher prices. If you’re shopping plans or providers, network breadth and facility fees matter.
• When care is complex, get a second opinion. Guidelines help, but you are not a guideline. (Also: your body didn’t read the memo.)

Conclusion: The Establishment Is a ToolSo Aim It Carefully

The medical establishment “in power” is best when it uses its leverage to expand access, reward quality, invest in
science, and communicate honestly. The medical establishment “out of power” is best when it uses its credibility to
defend evidence, highlight real-world harms, and improve policies through transparency and accountability.

In both cases, the goal isn’t to crown a permanent winner. It’s to build a system where expert knowledge can guide
care, democratic processes can set priorities, and market power can’t bully patients into paying luxury prices for
basic human needs. If that sounds hard, congratulationsyou’ve correctly identified the American healthcare system.
It’s complicated. But it’s not hopeless. And it definitely doesn’t need a full-moon board meeting to improve.

Real-World Experiences: from the Front Lines

Experience 1: The primary care “coverage surprise.”
A patient schedules a routine preventive visit expecting it to be free. The visit starts that wayuntil a new
symptom comes up (“By the way, I’ve had chest discomfort”) and the clinician does the right thing: they evaluate it.
Later, the bill arrives and the patient feels blindsided: the appointment is no longer purely “preventive,” and the
coverage rules treat it differently. In a world where the establishment is “in power,” preventive care is promoted,
but billing logic still governs. The lived experience is confusing: the system encouraged you to show up, then
punished you for mentioning something important. The lesson patients learn (sometimes unfairly) is to separate
checkups from problem visitsan example of how payment policy quietly shapes behavior.

Experience 2: The hospital administrator’s code-book marathon.
A mid-sized hospital rolls out a new quality initiative because reimbursement now depends more heavily on measured
performance. On paper, it’s noble: fewer readmissions, better follow-up, more care coordination. In practice, the
administrator spends weeks in meetings translating clinical reality into checklists and workflows that auditors will
accept. Clinicians grumble, not because they hate quality, but because the paperwork feels like a second job. This is
“establishment in power” at street level: policy turns into incentives, incentives turn into compliance work, and
compliance work competes with patient time. When it works, care improves. When it doesn’t, burnout rises.

Experience 3: The pain patient caught in guideline crossfire.
A patient with chronic pain has been stable on a long-standing treatment plan for years. After new prescribing
guidance and heightened scrutiny, their clinician becomes more cautious. The clinician isn’t trying to be cruel;
they’re trying to practice safely and avoid harm. But the patient experiences it as sudden mistrustextra visits,
new paperwork, more hoops, and sometimes dose changes that feel abrupt. This shows how “soft power” (guidelines and
professional standards) can feel like “hard power” when insurers, clinics, and regulators interpret recommendations
rigidly. Good guidelines aim to support safer care, but real life is messy. The human experience is anxiety, not an
abstract policy debate.

Experience 4: The researcher watching priorities shift.
A lab team has spent years building expertise in a niche areamethods, datasets, collaborations. Then funding
priorities shift. Suddenly, the grant landscape changes: new initiatives are in, older topics are out, and the team
has to decide whether to pivot or shrink. “In power” and “out of power” can be felt as stability versus volatility:
the difference between long-term investment and constant reinvention. The public often sees science as neutral and
linear, but researchers experience it as deeply shaped by budgets, directives, and which questions funders consider
urgent. In the best version of the system, priorities reflect public health needs. In the worst, they reflect
politics or headlines more than outcomes.

Experience 5: The patient advocate learning the grammar of policy.
A community advocate starts with a simple mission: make insulin (or oncology drugs, or asthma meds) affordable.
They quickly discover that “affordable” is not one switch. It’s rebates, formularies, negotiation rules, pharmacy
networks, manufacturer pricing, and insurance design. When the establishment is “out of power,” the advocate spends
more time building coalitions, collecting stories, and pushing incremental changes. When it’s “in power,” the same
advocate might be invited to listening sessions and asked for feedbackonly to realize that implementation details
can make or break the policy. The experience is equal parts hope and whiplash, with a side of learning acronyms you
never asked to learn.